Table 2.
Characteristic | SIR,a n/N (%) | Univariate, OR (95% CI) | P | Multivariable, OR (95% CI) | P |
---|---|---|---|---|---|
Index case characteristics | |||||
Age group, y | |||||
<1 | 0/6 (0) | Not estimated | Not estimated | ||
1–4 | 24/62 (39) | 2.5 (1.2–5.6) | .019 | 3.6 (1.2–11.3) | .026 |
5–14 | 17/86 (20) | Reference | Reference | Reference | Reference |
15–24 | 11/56 (20) | 1.0 (0.4–2.7) | .987 | 1.9 (0.6–6.4) | .280 |
25–44 | 21/85 (25) | 1.3 (0.6–3.2) | .520 | 8.0 (1.8–36.7) | .007 |
45–64 | 4/38 (11) | 0.5 (0.1–3.0) | .426 | 2.6(0.3–22.6) | .395 |
≥65 | 0/0 (0) | Not included | Not included | ||
Sex | |||||
Male | 30/122 (25) | 1.1 (0.6–1.9) | .706 | ||
Female | 47/211 (22) | Reference | Reference | ||
Site | |||||
Klerksdorp | 49/177 (28) | 1.8 (0.9–3.5) | .111 | ||
Edendale | 28/156 (18) | Reference | Reference | ||
Year | |||||
2013 | 19/108 (18) | Reference | .149 | ||
2014 | 58/225 (26) | 1.6 (0.9–3.2) | |||
HIV status | |||||
Uninfected | 59/220 (27) | Reference | Reference | Reference | Reference |
Infected | 18/113 (16) | 0.5 (0.2–1.3) | .158 | 0.2 (0.1–0.6) | .007 |
HIV status | |||||
Uninfected | 59/215 (27) | Reference | Reference | ||
Infected, receiving | 13/77 (17) | 0.5 (0.2–1.7) | .304 | ||
ART | 5/36 (14) | ||||
Infected, not receiving ART | 0.4 (0.2–0.9) | .034 | |||
Non-HIV underlying illnessd | |||||
Absent | 77/326 (24) | Not estimated | |||
Present | 0/7 (0) | ||||
Currently taking treatment for tuberculosis | |||||
No | 61/281 (22) | Reference | .002 | ||
Yes | 9/15 (60) | 5.4 (2.4–12.2) | |||
Alcohol use | |||||
No | 24/89 (27) | 2.8 (0.6–8.0) | .171 | ||
Yes | 5/43 (12) | Reference | |||
Smoking | |||||
No | 25/108 (34) | 1.5 (0.5–7.0) | .591 | ||
Yes | 4/24 (17) | Reference | |||
Influenza type | |||||
A | 71/294 (24) | Reference | .579 | ||
B | 12/39 (31) | 1.4 (0.4–4.7) | |||
Influenza type and subtype | |||||
H3N2 | 52/219 (24) | 1.4 (0.7–2.9) | .405 | ||
H1N1pdm09 | 12/65 (18) | Reference | Reference | ||
A (Unsubtyped) | 2/10 (20) | 1.1 (0.2–7.9) | .921 | ||
B | 11/39 (28) | 1.7 (0.7–6.4) | .404 | ||
Influenza Ct value | |||||
<30 | 64/243 (26) | 2.3 (1.1–4.8) | .036 | 2.7 (1.2–6.1) | .020 |
≥30 | 12/88 (14) | Reference | Reference | Reference | Reference |
Pneumococcal colonization | |||||
Yes | 37/131 (28) | 0.9 (0.4–2.4) | .909 | ||
No | 22/75 (29) | Reference | |||
Viral coinfectionb | |||||
Yes | 15/64 (23) | 1.0 (0.5–2.2) | .947 | ||
No | 62/269 (23) | Reference | |||
Received influenza vaccine | |||||
Yes | 0/5 (0) | Not estimated | |||
No | 69/298 (23) | ||||
Sore throat | |||||
Yes | 21/135 (16) | 0.4 (0.2–0.9) | .032 | ||
No | 50/173 (29) | Reference | Reference | ||
Myalgia | |||||
Yes | 9/64 (14) | 0.5 (0.2–1.4) | .176 | ||
No | 62/244 (25) | Reference | |||
Household contact characteristics | |||||
Age group, y | |||||
<1 | 3/6 (50) | 3.3 (0.6–13.6) | .095 | 1.6 (0.3–5.8) | .466 |
1–4 | 13/28 (46) | 2.8 (1.1–76) | .035 | 3.5 (1.2–10.3) | .021 |
5–14 | 19/82 (23) | Reference | Reference | Reference | Reference |
15–24 | 11/76 (14) | 0.6 (0.2–1.3) | .169 | 0.5 (0.2–1.2) | .115 |
25–44 | 16/84 (19) | 0.8 (0.4–1.7) | .528 | 0.8 (0.3–1.7) | .535 |
45–64 | 9/40 (23) | 1.0 (0.3–2.7) | .941 | 0.9 (0.3–3.0) | .832 |
≥65 | 6/17 (35) | 1.8 (0.6–5.5) | .294 | 2.4 (0.6–9.3) | .216 |
Sex | |||||
Male | 26/109 (24) | 1.0 (0.6–1.8) | .865 | ||
Female | 46/200 (23) | Reference | |||
HIV status | |||||
Uninfected | 38/140 (27) | Reference | .454 | ||
Infected | 5/26 (19) | 0.6 (0.2–2.1) | |||
Non-HIV underlying illnessd | |||||
Absent | 75/321 (23) | Reference | .573 | ||
Present | 2/12 (17) | 0.5 (0.1–2.9) | |||
Alcohol usec | |||||
No | 30/145 (21) | Reference | Reference | ||
Yes | 10/57 (18) | 0.8 (0.3–1.8) | .647 | ||
Smokingc | |||||
No | 33/169 (21) | Reference | Reference | ||
Yes | 7/33 (21) | 1.1 (0.4–2.8) | .825 | ||
Received influenza vaccine | |||||
Yes | 2/12 (17) | Reference | .734 | ||
No | 54/259 (21) | 1.3 (0.3–6.6) | |||
Share a bed with the index case | |||||
Yes | 29/86 (34) | 2.0 (1.1–3.8) | 0.021 | 2.7 (1.3–5.5) | 0.009 |
No | 45/226 (20) | Reference | Reference | Reference | |
Number of people in household | |||||
2–3 | 12/85 (14) | Reference | Reference | Reference | Reference |
4–6 | 43/195 (23) | 1.7 (0.7–4.0) | .213 | 2.3 (0.7–7.6) | .180 |
7+ | 22/53 (42) | 4.3 (1.4–13.3) | .012 | 6.1 (1.3–28.4) | .022 |
People per room | |||||
<3 | 52/225 (23) | Reference | .358 | ||
≥3 | 30/108 (28) | 1.3 (0.8–2.2) | |||
Number of children aged <5 years in house | |||||
≤2 | 64/315 (20) | Reference | <.001 | ||
>2 | 13/18 (72) | 10.2 (7.1–14.7) |
Missing data: Out of 87 index cases included in the analysis, data were missing for alcohol use (n = 4), smoking (n = 4), current tuberculosis treatment (n = 8), received influenza vaccine (n = 8), influenza cycle threshold value (n = 1), pneumococcal colonization (n = 34), symptoms (sore throat, runny nose, headache and myalgia) (n = 7). Out of 333 household contacts included in the analysis, data were missing for contact sex (n = 24), contact HIV status (n = 167), contact alcohol use (n = 15), contact smoking (n = 15), contact influenza vaccine receipt (n = 62), contact sharing a bed with index (n = 21). There were 70 (21%) household contacts missing 1 follow-up sample, 20 (6%) missing 2 samples, and 31 (9%) missing 3 samples.
OR and P values for all variables included in the multivariable models are displayed in the 2 right hand columns of the table. No pairwise interactions were included in the multivariable models as no interaction terms were found significant. Additional factors evaluated but not found to be associated with SIR were sharing eating utensils with the index case and avoiding contact with the sick household member.
Abbreviations: ART, antiretroviral therapy; CI, confidence interval; Ct, cycle threshold; HIV, human immunodeficiency virus; OR, odds ratio.
Secondary infection risk (SIR) = Number of secondary cases in the household/number of exposed household contacts.
Test positive on polymerase chain reaction for at least 1 of parainfluenza virus types 1–3, respiratory syncytial virus, enterovirus, human metapneumovirus, adenovirus or human rhinovirus.
Among individuals aged >15 years.
Asthma, other chronic lung disease, chronic heart disease, liver disease, renal disease, diabetes mellitus, immunocompromising conditions excluding HIV infection, neurological disease, or pregnancy. Comorbidities were considered absent in cases for which the medical records stated that the patient had no underlying medical condition or when there was no direct reference to that condition.